Latest News
Read our latest article – Rare disease clinical trials continue, thanks to new technology
01/03/2021
Rare Disease Day offers a valuable opportunity to raise awareness of rare disease and campaign for health equity. We are delighted to take part in Health Awareness’ Rare Diseases campaign this year, which in addition to our own contribution, features articles from Genetic Alliance UK, Rare Diseases International and EURORDIS to offer a diverse range […]
KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks
09/02/2021
We worked with KalVista Pharmaceuticals to study Oral KVD900 in Patients with Hereditary Angioedema (HAE) in this phase II clinical trial. Results included the observation that attacks treated with KVD900 significantly reduced use of rescue with 15% of KVD900 treated attacks rescued compared to 30% on placebo at 12 hours.
Simbec-Orion Streamlines Trial Execution With Veeva Clinical Applications
08/12/2020
Vault CTMS and Vault eTMF provide complete visibility into trials, enabling CRO to deliver value-added services to sponsors PLEASANTON, Calif.–(BUSINESS WIRE)–Veeva Systems (NYSE: VEEV) today announced that Simbec-Orion, a full-service contract research organization (CRO) specialized in clinical pharmacology, oncology, and rare diseases, is adopting Veeva Vault CTMS and Veeva Vault eTMF to digitize end-to-end clinical trial data, workflows, and documents. Veeva […]
Simbec-Orion and Oncodistinct Network agreement to strengthen early phase oncology research
01/10/2020
Providing oncology drug developers with the successful delivery of early phase oncology studies. Slough, Berkshire, United Kingdom: Simbec-Orion announced a charter agreement between the Oncodistinct Network and Simbec-Orion. The agreement strengthens the relationships between Simbec-Orion and the Oncodistinct network of oncology sites, who partner in operations and scientific expertise in the design and conduct of […]
Exvastat wins a 3.6 million euro grant for COVID-19 trial
19/05/2020
Congratulations to Cambridge Innovation Capital portfolio company Exvastat that has been awarded a grant from the prestigious Innovative Medicines Initiative. The grant will be used to reformulate and study imatinib in the treatment of Covid-19 associated Acute Respiratory Distress Syndrome (ARDS) in collaboration with Vrije Universiteit Amsterdam (VU Amsterdam), KABS Laboratories Inc. and Simbec-Orion. Read […]
Maintaining an agile and collaborative approach during the COVID-19 Pandemic
01/04/2020
Simbec-Orion COVID-19 Update 1 April 2020
Simbec-Orion Receives The “CRO Of The Year” Award At 2019 European Lifestars AwardsTM
21/01/2020
Celebrating success across life sciences London, UK, November 25th 2019. Simbec-Orion is pleased to announce that it has been recognised as the winner of the CRO of the Year award at the 2019 Lifestars AwardsTM. Lifestars is a celebration of the success stories, innovations, transformational deals and the people, teams and organisations that play such […]
